Clinical Trial: NRG GY033

NRG GY033

Status: Temporarily Closed

A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination with Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumor

GY033 is temporarily closed to accrual, effective April 26, 2024.